| 10.53 -1.47 (-12.25%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 12.68 | 1-year : | 13.54 |
| Resists | First : | 10.85 | Second : | 11.6 |
| Pivot price | 0 | |||
| Supports | First : | 9.65 | Second : | 8.03 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 11.6 | Low : | 9.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RTSN ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.
Fri, 09 Oct 2026
Retension Pharmaceuticals, Clinical-Stage Developer of Hypertension Therapies, Files for Nasdaq Capital Market IPO - TradingView
Fri, 09 Oct 2026
RTSN Interactive Stock Chart | Retension Pharmaceuticals, Inc. Common Stock Stock - Yahoo Finance
Fri, 09 Oct 2026
RTSN Price History for Retension Pharmaceuticals Stock - Barchart.com
Fri, 09 Oct 2026
RTSN IPO News - Hypertension drug developer Retension Pharmaceuticals prices upsized IPO at $12 midpoint - www.renaissancecapital.com
Fri, 09 Oct 2026
Retension Pharmaceuticals prices upsized IPO at $12 per share (RTSN:Pending) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 8 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.04 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|